Merck & Company
Merck is a global pharmaceutical company that develops and sells prescription medicines, vaccines and animal health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiovascular conditions and other major therapeutic areas. Keytruda, its leading cancer immunotherapy, is a major revenue driver, while Gardasil is another important vaccine franchise. Its Animal Health business provides medicines, vaccines and healthcare solutions for livestock and companion animals.
默克是一家全球领先的制药公司,主要研发和销售处方药、疫苗及动物保健产品。其制药业务专注于肿瘤、传染病、心血管疾病及其他主要治疗领域。Keytruda(可瑞达)是公司的核心癌症免疫治疗药物,也是重要的收入来源;Gardasil(佳达修)则是其另一项重要疫苗产品线。此外,动物保健业务为家畜及伴侣动物提供药物、疫苗和医疗解决方案。
The forecast figures are tipranks’s, read on 2026-11-16 and linked below.
SmartChecker Merck & Company Forecast
The forecast in short
tipranks records 22 analyst ratings on Merck & Company and summarises them as “Moderate Buy”. Their average 12-month price target is USD 162.14 (9.73% Upside). Its tipranks score is 8 out of 10 — Outperform. These are tipranks’s figures as SmartChecker read them on 2026-11-16, not SmartChecker’s own view, and nothing here is advice to buy or sell.
Market cap
USD 364.26 B
≈ RM 1.49T
Share price
USD 147.76
≈ RM 604.77
#40World ranking
tipranks score
Outperform
Analyst ratings
Moderate Buy
- Buy15 68%
- Hold7 32%
- Sell0 0%
tipranks’s own summary of the 22 ratings above.
12 months price forecast
USD 162.14 9.73% Upside
As tipranks publishes it. SmartChecker has not recalculated any of it.
Analyst profiles. Who made each call, and when.
| Analyst | From | Position | Target price | Dated |
|---|---|---|---|---|
| Carter Gould | Cantor Fitzgerald | Hold | USD 155 | 2026-11-11 |
| Louise Chen | Scotiabank | Buy | USD 180 | 2026-11-10 |
| Trung Huynh | RBC Capital | Hold | USD 140 | 2026-11-05 |
| Elmar Kraus | DZ BANK AG | Hold | USD 153 | 2026-11-03 |
| Daina Graybosch | Leerink Partners | Buy | USD 162 | 2026-11-02 |
| Ilya Zubkov | Freedom Capital Markets | Hold | USD 140 | 2026-11-02 |
| Jason Gerberry | Bank of America Securities | Buy | USD 165 | 2026-10-30 |
| Evan Seigerman | BMO Capital | Buy | USD 170 | 2026-10-30 |
| Terence Flynn | Morgan Stanley | Buy | USD 174 | 2026-10-30 |
| Chris Schott | J.P. Morgan | Buy | USD 175 | 2026-10-30 |
| Vamil Divan | Guggenheim | Buy | USD 171 | 2026-10-29 |
| Emily Field | Barclays | Buy | USD 180 | 2026-10-28 |
| Geoff Meacham | Citi | Hold | USD 145 | 2026-10-27 |
| Mohit Bansal | Wells Fargo | Buy | USD 165 | 2026-10-26 |
| Courtney Breen | Bernstein | Hold | USD 105 | 2026-10-25 |
| Michael Yee | UBS | Buy | USD 175 | 2026-10-24 |
| Asad Haider | Goldman Sachs | Buy | USD 155 | 2026-10-22 |
| Steve Scala | TD Cowen | Hold | USD 155 | 2026-09-22 |
| Nico Chen | DBS | Buy | USD 180 | 2026-09-11 |
| Rajesh Kumar | HSBC | Buy | USD 172 | 2026-09-10 |
| Alexandria Hammond | Wolfe Research | Buy | USD 180 | 2026-08-25 |
| Jasper Hellweg | Argus Research | Buy | USD 170 | 2026-08-24 |
| Luisa Hector | Berenberg Bank | Hold | USD 127 | 2026-08-05 |
| Unknown Analyst | Jefferies | Buy | USD 138 | 2026-05-19 |
| Hans Engel | Erste Group | Hold | N/A | 2026-05-05 |
| Natalya Davies | Rothschild & Co Redburn | Buy | USD 179 | 2026-04-17 |
| James Shin | Deutsche Bank | Buy | USD 150 | 2026-02-13 |
Show moreShow less
Investment Strengths
Diversified product growth多元化产品增长
Revenue growth is supported by multiple therapeutic and animal-health franchises rather than a single product. Continued contributions from new products, oncology and animal health broaden the earnings base and provide durable commercial momentum over the next several quarters.公司的收入增长由多个治疗领域及动物保健业务共同推动,而非依赖单一产品。新产品、肿瘤药物及动物保健业务的持续贡献,有助于扩大整体盈利基础,并在未来几个季度保持稳定且可持续的商业增长动力。
Pipeline strength强大的研发管线
Late-stage clinical and regulatory progress strengthens Merck’s ability to replenish growth as mature products age. Positive results across oncology, vaccines and pulmonary hypertension diversify future launch opportunities and improve the durability of the portfolio.后期临床试验及监管审批方面的持续进展,增强了 Merck 在成熟产品逐渐进入生命周期后补充增长动力的能力。肿瘤治疗、疫苗及肺动脉高压领域取得的积极成果,进一步丰富了公司未来新产品上市的机会,并提升整体产品组合的长期增长潜力。
Strong cash generation强劲的现金创造能力
Substantial operating and free cash flow gives Merck capacity to fund research, launches, capital needs, dividends and business development internally. Strong cash conversion supports financial resilience even while recent free-cash-flow growth has moderated.可观的经营现金流和自由现金流,使 Merck 能够依靠内部资金支持研发、新产品上市、资本支出、股息支付及业务拓展。强劲的现金转化能力为公司提供了稳健的财务基础,即使近期自由现金流增长有所放缓,仍具备较强的财务韧性。
People also ask
What is the 12-month price target for Merck & Company (MRK)?
tipranks publishes an average 12-month price target of USD 162.14 (9.73% Upside), as SmartChecker read it on 2026-11-16. The highest target is USD 180 and the lowest is USD 105. A price target is an analyst’s estimate of where a share might trade, not a promise, and SmartChecker gives no investment advice.
See tipranks’s own page ↗How many analysts cover Merck & Company (MRK)?
tipranks records 22 analyst ratings: 15 buy, 7 hold and 0 sell, which it summarises as “Moderate Buy”, as SmartChecker read it on 2026-11-16.
See tipranks’s own page ↗What is the tipranks score for Merck & Company (MRK)?
tipranks scores it 8 out of 10 and calls that “Outperform”, as SmartChecker read it on 2026-11-16. The score is tipranks’s, not SmartChecker’s, and SmartChecker does not rate listed shares.
See tipranks’s own page ↗Is this SmartChecker’s own forecast for Merck & Company?
No. Every figure on this page is published by tipranks, copied on 2026-11-16 with a link to the original, and not recalculated. SmartChecker assesses financial companies in Malaysia against the public registers; it makes no forecast of its own and holds no licence to advise on securities.
See tipranks’s own page ↗Member reviews. Members’ own ratings and words, not SmartChecker’s rating.
These ratings and words are written by SmartChecker members and published immediately without administrator approval. SmartChecker does not rate listed companies: a rating here belongs to whoever wrote it, it counts towards no score of ours, and nothing in it is advice.
Disclaimer
SmartChecker provides informational and financial market news only and does not provide investment, financial or legal advice.
